Methods and compositions for regulating iron homeostasis by modulation of bmp-6

a technology of iron homeostasis and bmp-6, which is applied in the field of bmp6 and bmp6 protein specific reagents, can solve the problems of iron deposits in these organs and tissues, and achieve the effects of reducing hepcidin expression, increasing serum iron level, and increasing serum transferrin saturation

Inactive Publication Date: 2021-12-16
THE GENERAL HOSPITAL CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]The invention provides methods for treating a subject who has one or more symptoms of hereditary hemochromatosis, the symptoms selected from the group consisting of: in...

Problems solved by technology

In humans, hereditary hemochromatosis (HH) is a common autosomal recessive genetic disease caused by hyperabsorption of dietary iron leading to an iron overloa...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for regulating iron homeostasis by modulation of bmp-6
  • Methods and compositions for regulating iron homeostasis by modulation of bmp-6
  • Methods and compositions for regulating iron homeostasis by modulation of bmp-6

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of cDNA

[0151]cDNA encoding codon optimized DRAGON.Fc was generated by GenScript Corporation (Piscataway, N.J. 08854), based on the human DRAGON protein sequence upstream of the predicted GPI anchor (UniProtKB / Swiss-Prot accession Q6NW40, amino acids 1-409) and the human IgG1 Fc sequence (from the Signal pIg plus vector (R&D Systems) and GenBank AF150959).

example 2

n and Purification of DRAGON.Fc and HJV.Fc

[0152]cDNA encoding DRAGON.Fc was transfected using 293fectin (Invitrogen) into Freestyle 293-F cells (Invitrogen) according to the manufacturer's instructions. Transfected cells were cultured in GIBCO Freestyle 293 Expression medium (Invitrogen) shaking at 110 RPM in a humidified 8% CO2 incubator at 37° C. Seven days after transfection, cells were pelleted by centrifugation and DRAGON.Fc was purified from the media via one-step Protein A affinity chromatography using Hi-Trap rProtein A FF columns (Amersham Biosciences) as described in Babbitt, J. L., et al. 2005. J. Biol. Chem. 280:29820-29827. HJV.Fc was produced as described in Babitt, J. L., et al. 2007. J Clin Invest. 117:1933-9. To determine purity and to quantify protein concentration, DRAGON.Fc and HJV.Fc were subjected to reducing SDS-PAGE followed by Bio-safe Coomassie blue staining (Bio-Rad) as well as Western blot with anti-HJV antibody (Babitt, J. L., et al. 2006. Nat. Genet. 38...

example 3

n of BMP-6

[0153]Purified recombinant human BMP-6 was prepared as previously described. (Simic, P., et al. 2006. J Biol Chem. 281:25509-21). Lyophilized BMP-6 was dissolved in 20 mM sodium acetate, 5% mannitol solution, pH 4.0 for animal injections.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Densityaaaaaaaaaa
Electrical conductanceaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 15 / 599,420, filed on May 18, 2017, which is a continuation of U.S. patent application Ser. No. 13 / 625,049, filed Sep. 24, 2012, now abandoned, which is a continuation of U.S. patent application Ser. No. 12 / 618,319, filed Nov. 13, 2009, which issued as U.S. Pat. No. 8,318,167 on Nov. 27, 2012, that claims priority from U.S. Provisional Patent Application No. 61 / 141,155, filed Dec. 29, 2008 and U.S. Provisional Patent Application No. 61 / 114,290, filed Nov. 13, 2008, the contents of which are incorporated herein by reference in their entireties.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH[0002]This invention was made with government support under Grant Nos. DK071837 and DK075846, awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.REFERENCE TO A SEQUENCE LISTING[0003]The instant application contains a Sequence Listing which has been sub...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/18C07K16/22A61P7/06C12N15/113G01N33/53
CPCC07K16/18C07K16/22A61K2039/505C12N15/113G01N33/53A61P7/06C07K2317/76C07K2317/34A61K38/1709C07K2319/30
Inventor LIN, HERBERT Y.BABITT, JODIE
Owner THE GENERAL HOSPITAL CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap